Internal Mammary Node Irradiation Improves Survival for Patients with Clinical Stage II-III Breast Cancer and Treated with Neoadjuvant Chemotherapy
J. Luo,K. Jin,X. Chen,Z. Yang,L. Zhang,X. Mei,J. Ma,Z. Zhang,Z. Shao,X. Yu,X. Guo
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.535
2017-01-01
Abstract:Although the survival benefit of postoperative radiotherapy has been confirmed in randomized trials and meta-analysis, the inclusion of internal mammary node irradiation (IMNI) is still controversial. The increasing use of neoadjuvant chemotherapy (NAC) has made this issue more complicated, there is limited data to assess the value of IMNI in NAC settings, and patients who received NAC were usually excluded in most IMNI studies. In this study, we aim to evaluate the value of IMNI in clinical stage II-III breast cancer patients who were treated with NAC. We retrospectively identified 497 clinical stage II-III breast cancer patients who underwent NAC, surgery and postoperative radiotherapy with (n = 236) or without (n = 261) IMNI in our center between August 2005 and December 2013. All patients received 2-8 cycles (median, 4 cycles) anthracycline- and taxane-based preoperative chemotherapy. Four hundred seventy (94.6%) and 27 (5.4%) patients underwent mastectomy and breast conserving surgery, respectively. The effects of IMNI on disease-free survival (DFS) and overall survival (OS) were evaluated by Kaplan-Meier method and compared using the log-rank test. Prognostic factors associated with survival were evaluated by univariate and multivariate analysis. The median age of all patients was 49 years old (range, 21-80 years). Compared with patients without IMNI, most of patients in IMNI group had more advanced clinical T stage (T3-4), pathological T and N stage (P < 0.01). With a median follow-up time of 50 months, 19 and 119 patients developed LRR and developed distant metastasis, respectively, and 40 patients died of breast cancer. For the whole population, IMNI didn’t significant influence the survival outcome in univariate analysis, the 5-year DFS and OS was 70.9% and 91.2% in no-IMNI group and 73.9% and 89.9% in IMNI group, respectively (P = NS). For the subgroup of 329 patients with pathological positive axillary lymph nodes (ypN+) after NAC, IMNI significantly improved 5-year DFS (59.4% vs 68.3%, P = 0.046), but didn’t significant influence the 5-year OS (84.5% vs 88.1%, P = 0.647). On multivariate analysis, IMNI was independent prognostic factor for DFS (hazard ratio [HR], 0.610; 95% confidence interval [CI], 0.423-0.88; P = 0.008), but wasn’t associated with OS (HR, 0.752; 95% [CI], 0.374-1.512; P = 0.423). In addition to IMNI, clinical T stage, pathological N stage, and HER2 status were independent prognostic factors for DFS. Younger age at diagnosis (<40 years), advanced clinical T stage and pathological N stage, negative ER status were independently associated with decreased OS. IMNI was significantly associated with improved DFS for patients with clinical stage II-III breast cancer and receiving NAC, especially for ypN+ patients. Further prospective studies are warranted to identify the effect of IMNI in the NAC setting.